View ValuationSilco Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Silco Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳19.20, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 21% over the past three years.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 24Silco Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 29, 2026Silco Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 26Silco Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silco Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 25Silco Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 30, 2025Silco Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 30, 2025お知らせ • Nov 19Silco Pharmaceuticals Limited announces Annual dividend, payable on February 18, 2026Silco Pharmaceuticals Limited announced Annual dividend of BDT 0.1100 per share payable on February 18, 2026, ex-date on December 17, 2025 and record date on December 15, 2025.お知らせ • Nov 18Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026, at 11:30 Central Asia Standard Time. Location: hybrid system:, at registered office premises., Bangladeshお知らせ • Nov 11Silco Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Nov 17, 2025Silco Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Nov 17, 2025お知らせ • Apr 21Silco Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silco Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025お知らせ • Jan 27Silco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025お知らせ • Nov 18Silco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 21, 2024Silco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 21, 2024New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Revenue is less than US$5m (৳422m revenue, or US$3.5m). Market cap is less than US$100m (৳1.63b market cap, or US$13.6m).Declared Dividend • Nov 06Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 9th December 2024 Payment date: 16th February 2025 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (66% earnings payout ratio) but not adequately covered by cash flows (92% cash payout ratio). The dividend has increased by an average of 13% per year over the past 4 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 27% to shift the payout ratio to a potentially unsustainable range, which is more than the 23% EPS decline seen over the last 5 years.お知らせ • Nov 04Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladeshお知らせ • Oct 25Silco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 31, 2024Silco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳21.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 27% over the past three years.Valuation Update With 7 Day Price Move • May 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ৳21.30, the stock trades at a trailing P/E ratio of 51.7x. Average trailing P/E is 31x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 7.5% over the past three years.Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.16 (vs ৳0.21 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.16 (down from ৳0.21 in 3Q 2023). Revenue: ৳110.0m (down 12% from 3Q 2023). Net income: ৳17.1m (down 21% from 3Q 2023). Profit margin: 16% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Apr 26Silco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Silco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024Reported Earnings • Feb 08Second quarter 2024 earnings released: EPS: ৳0.12 (vs ৳0.15 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.12 (down from ৳0.15 in 2Q 2023). Revenue: ৳104.9m (flat on 2Q 2023). Net income: ৳12.8m (down 19% from 2Q 2023). Profit margin: 12% (down from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.80, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.8% over the past three years.お知らせ • Jan 24Silco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 30, 2024Silco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 30, 2024New Risk • Jan 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (157% cash payout ratio). Large one-off items impacting financial results. Revenue is less than US$5m (৳437m revenue, or US$4.0m). Market cap is less than US$100m (৳2.43b market cap, or US$22.2m).Upcoming Dividend • Dec 12Upcoming dividend of ৳0.30 per share at 1.3% yieldEligible shareholders must have bought the stock before 19 December 2023. Payment date: 12 February 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.43b market cap, or US$22.1m).お知らせ • Nov 29Silco Pharmaceuticals Limited Recommends Cash Dividend for All Shareholders Excluding Directors for the Year Ended June 30, 2023Silco Pharmaceuticals Limited recommended 3% cash dividend for all shareholders excluding Directors for the year ended June 30, 2023.お知らせ • Nov 28Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024, at 11:30 Bangladesh Standard Time. Agenda: To approve the Dividend Declaration.お知らせ • Nov 27Silco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 29, 2023Silco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 29, 2023お知らせ • Nov 20Silco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Nov 26, 2023Silco Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Nov 26, 2023New Risk • Jun 15New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳418m (US$3.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.47b market cap, or US$22.7m).Buying Opportunity • May 29Now 22% undervaluedOver the last 90 days, the stock is up 4.7%. The fair value is estimated to be ৳31.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has grown by 4.4%.お知らせ • Jan 12Silco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited approved 5% cash dividend for the year ended June 30, 2022.Upcoming Dividend • Nov 29Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 06 December 2022. Payment date: 09 February 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.3%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 08Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited announced that the Board of Directors has recommended 5% cash dividend for all shareholders excluding Directors only for the year ended June 30, 2022.Buying Opportunity • Jul 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.2%. The fair value is estimated to be ৳29.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last year. Earnings per share has declined by 50%.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.40, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 29% over the past year.Reported Earnings • May 29Third quarter 2021 earnings released: EPS: ৳0.32 (vs ৳0.25 in 3Q 2020)Third quarter 2021 results: EPS: ৳0.32 (up from ৳0.25 in 3Q 2020). Revenue: ৳188.7m (down 5.1% from 3Q 2020). Net income: ৳33.3m (up 28% from 3Q 2020). Profit margin: 18% (up from 13% in 3Q 2020). The increase in margin was driven by lower expenses.Buying Opportunity • May 26Now 20% undervaluedOver the last 90 days, the stock is up 5.7%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.Buying Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.5%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Apr 04Now 20% undervaluedOver the last 90 days, the stock is up 4.4%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳27.10, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 17% over the past year.Buying Opportunity • Feb 15Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% per annum over the last 3 years. Earnings per share has declined by 25% per annum over the last 3 years.Upcoming Dividend • Dec 14Upcoming dividend of ৳1.00 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 15 February 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.8%. Within top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳30.90, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 44% over the past year.Reported Earnings • Feb 24Second quarter 2021 earnings released: EPS ৳0.12 (vs ৳0.23 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳121.3m (down 29% from 2Q 2020). Net income: ৳12.4m (down 48% from 2Q 2020). Profit margin: 10% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue.お知らせ • Nov 03Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Bangladesh Standard Time. Agenda: To recommend cash dividend for the year ended on June 30, 2020.お知らせ • Oct 05Silco Pharmaceuticals Limited Signs First Export Agreement with Zaid Elyas Adil LtdSilco Pharmaceuticals Limited signed its first export agreement with ZAID ELYAS ADIL LTD, Afghanistan. The Company will export total of 13 different medicines to Afghanistan for next 5 years commencing from August 2020. Total export value (estimated) will be USD 3,80,000.00. First export value (as per PI) will be USD 26,780.00 against 13 different medicines to Afghanistan and estimated profit will be 30% against the export.お知らせ • Jul 06Silco Pharmaceuticals Limited to Report Q3, 2020 Results on Jun 29, 2020Silco Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jun 29, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Silco Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DSE:SILCOPHL - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026409341773N/A12/31/202543142765N/A9/30/2025433421581N/A6/30/202543243877N/A3/31/202542947-2487N/A12/31/202443050-5111N/A9/30/202442352-792N/A6/30/202441046084N/A3/31/2024422433497N/A12/31/20234364845134N/A9/30/20234375020156N/A6/30/202346569-1180N/A3/31/202341868-39187N/A12/31/202247482-42163N/A9/30/20225047914171N/A6/30/20225598463169N/A3/31/20225528864207N/A12/31/202156187N/AN/AN/A9/30/202154686-47243N/A6/30/202160185-119257N/A3/31/202168184-92206N/A12/31/202069176N/AN/AN/A9/30/202074088-26158N/A6/30/202073483-23147N/A3/31/2020814163-12135N/A12/31/2019856167N/AN/AN/A9/30/2019930168N/A124N/A6/30/2019919162N/A81N/A3/31/2019920106N/A152N/A12/31/2018924105N/A101N/A9/30/2018910104N/A86N/A6/30/2018918105N/A86N/A6/30/2017907103N/A215N/A6/30/2016886119N/A181N/A12/31/2015851117N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SILCOPHLの予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SILCOPHLの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SILCOPHLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SILCOPHLの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SILCOPHLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SILCOPHLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/08 18:58終値2026/07/08 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Silco Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳19.20, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 21% over the past three years.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 24Silco Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 29, 2026Silco Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 26Silco Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silco Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 25Silco Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 30, 2025Silco Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 30, 2025
お知らせ • Nov 19Silco Pharmaceuticals Limited announces Annual dividend, payable on February 18, 2026Silco Pharmaceuticals Limited announced Annual dividend of BDT 0.1100 per share payable on February 18, 2026, ex-date on December 17, 2025 and record date on December 15, 2025.
お知らせ • Nov 18Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026, at 11:30 Central Asia Standard Time. Location: hybrid system:, at registered office premises., Bangladesh
お知らせ • Nov 11Silco Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Nov 17, 2025Silco Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Nov 17, 2025
お知らせ • Apr 21Silco Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silco Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025
お知らせ • Jan 27Silco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025
お知らせ • Nov 18Silco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 21, 2024Silco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 21, 2024
New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Revenue is less than US$5m (৳422m revenue, or US$3.5m). Market cap is less than US$100m (৳1.63b market cap, or US$13.6m).
Declared Dividend • Nov 06Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 9th December 2024 Payment date: 16th February 2025 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (66% earnings payout ratio) but not adequately covered by cash flows (92% cash payout ratio). The dividend has increased by an average of 13% per year over the past 4 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 27% to shift the payout ratio to a potentially unsustainable range, which is more than the 23% EPS decline seen over the last 5 years.
お知らせ • Nov 04Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
お知らせ • Oct 25Silco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 31, 2024Silco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳21.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 27% over the past three years.
Valuation Update With 7 Day Price Move • May 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ৳21.30, the stock trades at a trailing P/E ratio of 51.7x. Average trailing P/E is 31x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 7.5% over the past three years.
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.16 (vs ৳0.21 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.16 (down from ৳0.21 in 3Q 2023). Revenue: ৳110.0m (down 12% from 3Q 2023). Net income: ৳17.1m (down 21% from 3Q 2023). Profit margin: 16% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 26Silco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Silco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024
Reported Earnings • Feb 08Second quarter 2024 earnings released: EPS: ৳0.12 (vs ৳0.15 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.12 (down from ৳0.15 in 2Q 2023). Revenue: ৳104.9m (flat on 2Q 2023). Net income: ৳12.8m (down 19% from 2Q 2023). Profit margin: 12% (down from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.80, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.8% over the past three years.
お知らせ • Jan 24Silco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 30, 2024Silco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 30, 2024
New Risk • Jan 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (157% cash payout ratio). Large one-off items impacting financial results. Revenue is less than US$5m (৳437m revenue, or US$4.0m). Market cap is less than US$100m (৳2.43b market cap, or US$22.2m).
Upcoming Dividend • Dec 12Upcoming dividend of ৳0.30 per share at 1.3% yieldEligible shareholders must have bought the stock before 19 December 2023. Payment date: 12 February 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.43b market cap, or US$22.1m).
お知らせ • Nov 29Silco Pharmaceuticals Limited Recommends Cash Dividend for All Shareholders Excluding Directors for the Year Ended June 30, 2023Silco Pharmaceuticals Limited recommended 3% cash dividend for all shareholders excluding Directors for the year ended June 30, 2023.
お知らせ • Nov 28Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024, at 11:30 Bangladesh Standard Time. Agenda: To approve the Dividend Declaration.
お知らせ • Nov 27Silco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 29, 2023Silco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 29, 2023
お知らせ • Nov 20Silco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Nov 26, 2023Silco Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Nov 26, 2023
New Risk • Jun 15New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳418m (US$3.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.47b market cap, or US$22.7m).
Buying Opportunity • May 29Now 22% undervaluedOver the last 90 days, the stock is up 4.7%. The fair value is estimated to be ৳31.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has grown by 4.4%.
お知らせ • Jan 12Silco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited approved 5% cash dividend for the year ended June 30, 2022.
Upcoming Dividend • Nov 29Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 06 December 2022. Payment date: 09 February 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.3%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 08Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited announced that the Board of Directors has recommended 5% cash dividend for all shareholders excluding Directors only for the year ended June 30, 2022.
Buying Opportunity • Jul 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.2%. The fair value is estimated to be ৳29.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last year. Earnings per share has declined by 50%.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.40, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 29% over the past year.
Reported Earnings • May 29Third quarter 2021 earnings released: EPS: ৳0.32 (vs ৳0.25 in 3Q 2020)Third quarter 2021 results: EPS: ৳0.32 (up from ৳0.25 in 3Q 2020). Revenue: ৳188.7m (down 5.1% from 3Q 2020). Net income: ৳33.3m (up 28% from 3Q 2020). Profit margin: 18% (up from 13% in 3Q 2020). The increase in margin was driven by lower expenses.
Buying Opportunity • May 26Now 20% undervaluedOver the last 90 days, the stock is up 5.7%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.
Buying Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.5%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Apr 04Now 20% undervaluedOver the last 90 days, the stock is up 4.4%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳27.10, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 17% over the past year.
Buying Opportunity • Feb 15Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% per annum over the last 3 years. Earnings per share has declined by 25% per annum over the last 3 years.
Upcoming Dividend • Dec 14Upcoming dividend of ৳1.00 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 15 February 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.8%. Within top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳30.90, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 44% over the past year.
Reported Earnings • Feb 24Second quarter 2021 earnings released: EPS ৳0.12 (vs ৳0.23 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳121.3m (down 29% from 2Q 2020). Net income: ৳12.4m (down 48% from 2Q 2020). Profit margin: 10% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue.
お知らせ • Nov 03Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Bangladesh Standard Time. Agenda: To recommend cash dividend for the year ended on June 30, 2020.
お知らせ • Oct 05Silco Pharmaceuticals Limited Signs First Export Agreement with Zaid Elyas Adil LtdSilco Pharmaceuticals Limited signed its first export agreement with ZAID ELYAS ADIL LTD, Afghanistan. The Company will export total of 13 different medicines to Afghanistan for next 5 years commencing from August 2020. Total export value (estimated) will be USD 3,80,000.00. First export value (as per PI) will be USD 26,780.00 against 13 different medicines to Afghanistan and estimated profit will be 30% against the export.
お知らせ • Jul 06Silco Pharmaceuticals Limited to Report Q3, 2020 Results on Jun 29, 2020Silco Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jun 29, 2020